POAI Quote, Financials, Valuation and Earnings

DarioHealth Corp. has a net margin of -2156852.78% compared to Predictive Oncology, Inc.'s net margin of -41.48%. Predictive Oncology, Inc.'s return on equity of -1065.31% beat DarioHealth Corp.'s return on equity of -41.55%.

Predictive Oncology, Inc. has a consensus price target of --, signalling upside risk potential of 716.7%. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 54.01%. Given that Predictive Oncology, Inc. has higher upside potential than DarioHealth Corp., analysts believe Predictive Oncology, Inc. is more attractive than DarioHealth Corp..

Predictive Oncology, Inc. has a beta of 1.354, which suggesting that the stock is 35.357% more volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.

Predictive Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Predictive Oncology, Inc. pays -- of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend.

Predictive Oncology, Inc. quarterly revenues are $3.6K, which are smaller than DarioHealth Corp. quarterly revenues of $5M. Predictive Oncology, Inc.'s net income of -$77.6M is lower than DarioHealth Corp.'s net income of -$2.1M. Notably, Predictive Oncology, Inc.'s price-to-earnings ratio is -- while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Predictive Oncology, Inc. is 16.89x versus 6.58x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GoodRx Holdings, Inc. has a net margin of -2156852.78% compared to Predictive Oncology, Inc.'s net margin of 0.57%. Predictive Oncology, Inc.'s return on equity of -1065.31% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

Predictive Oncology, Inc. has a consensus price target of --, signalling upside risk potential of 716.7%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $5.09 which suggests that it could grow by 85.74%. Given that Predictive Oncology, Inc. has higher upside potential than GoodRx Holdings, Inc., analysts believe Predictive Oncology, Inc. is more attractive than GoodRx Holdings, Inc..

Predictive Oncology, Inc. has a beta of 1.354, which suggesting that the stock is 35.357% more volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

Predictive Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Predictive Oncology, Inc. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

Predictive Oncology, Inc. quarterly revenues are $3.6K, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. Predictive Oncology, Inc.'s net income of -$77.6M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Predictive Oncology, Inc.'s price-to-earnings ratio is -- while GoodRx Holdings, Inc.'s PE ratio is 31.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Predictive Oncology, Inc. is 16.89x versus 1.26x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -2156852.78% compared to Predictive Oncology, Inc.'s net margin of 11.54%. Predictive Oncology, Inc.'s return on equity of -1065.31% beat National Research Corp.'s return on equity of 61.55%.

Predictive Oncology, Inc. has a consensus price target of --, signalling upside risk potential of 716.7%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Predictive Oncology, Inc. has higher upside potential than National Research Corp., analysts believe Predictive Oncology, Inc. is more attractive than National Research Corp..

Predictive Oncology, Inc. has a beta of 1.354, which suggesting that the stock is 35.357% more volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Predictive Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.12 per share. Predictive Oncology, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Predictive Oncology, Inc. quarterly revenues are $3.6K, which are smaller than National Research Corp. quarterly revenues of $34.6M. Predictive Oncology, Inc.'s net income of -$77.6M is lower than National Research Corp.'s net income of $4M. Notably, Predictive Oncology, Inc.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 22.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Predictive Oncology, Inc. is 16.89x versus 2.65x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -2156852.78% compared to Predictive Oncology, Inc.'s net margin of 9.46%. Predictive Oncology, Inc.'s return on equity of -1065.31% beat Spok Holdings, Inc.'s return on equity of 10.88%.

Predictive Oncology, Inc. has a consensus price target of --, signalling upside risk potential of 716.7%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 60.06%. Given that Predictive Oncology, Inc. has higher upside potential than Spok Holdings, Inc., analysts believe Predictive Oncology, Inc. is more attractive than Spok Holdings, Inc..

Predictive Oncology, Inc. has a beta of 1.354, which suggesting that the stock is 35.357% more volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

Predictive Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.53% to investors and pays a quarterly dividend of $0.31 per share. Predictive Oncology, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

Predictive Oncology, Inc. quarterly revenues are $3.6K, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. Predictive Oncology, Inc.'s net income of -$77.6M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, Predictive Oncology, Inc.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Predictive Oncology, Inc. is 16.89x versus 1.95x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.